Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBB-002
- Development stage
- Preclinical
- Lead developer
- RophiBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
RBB-002 is an engineered aflibercept biobetter being developed by RophiBio for the treatment of neovascular age-related macular degeneration (nAMD). It is a recombinant fusion protein designed to neutralize both vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), which are key drivers of pathological angiogenesis and vascular leakage in the retina. The molecule features Fc-engineering intended to improve its therapeutic properties, such as extended half-life or enhanced binding affinity, compared to the reference product aflibercept. RBB-002 is currently in the preclinical stage of development.
- Other names
- engineered afliberceptaflibercept biobetter
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on RBB-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBB-002.